A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

Prior treatment

• Active rheumatic autoimmune disease other than SSc requiring treatment with disease-modifying therapy
• Pregnant or breastfeeding, or intending to become pregnant during the study or within 4 months after the final dose of study drug
• Major surgery within 8 weeks prior to screening, or major planned surgery during the study or within 3 months after the final dose

Other illness

• Pulmonary disease with forced vital capacity (FVC) ≤ 50% of predicted
• History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders
• History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
• Positive hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody test at screening

Lab values

• Any serious medical condition or abnormality in clinical laboratory tests

• Weight of 45-150 kg at screening
• Diagnosis of SSc, as defined by 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria and ≤ 10 years disease duration from first non-Raynaud's symptom
• Agreement to remain abstinent or use an effective contraceptive method among males and females with childbearing potential for 4 months after last dose of study drug
• No clinically significant change in eligibility status
• Completion of the MAD and ability to roll over into the OSE within 5 days